MA42519A - Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique - Google Patents

Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique

Info

Publication number
MA42519A
MA42519A MA042519A MA42519A MA42519A MA 42519 A MA42519 A MA 42519A MA 042519 A MA042519 A MA 042519A MA 42519 A MA42519 A MA 42519A MA 42519 A MA42519 A MA 42519A
Authority
MA
Morocco
Prior art keywords
treatment
diabetic nephropathy
pde4 inhibitor
pde4
inhibitor
Prior art date
Application number
MA042519A
Other languages
English (en)
Inventor
Guido Hanauer
Masatoshi Hazama
Takanori Matsuo
Stephanie Vollert
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of MA42519A publication Critical patent/MA42519A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA042519A 2015-07-29 2016-07-28 Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique MA42519A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562198213P 2015-07-29 2015-07-29

Publications (1)

Publication Number Publication Date
MA42519A true MA42519A (fr) 2018-06-06

Family

ID=56551407

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042519A MA42519A (fr) 2015-07-29 2016-07-28 Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique

Country Status (9)

Country Link
US (1) US20200179369A1 (fr)
EP (1) EP3328381A1 (fr)
JP (1) JP2018521077A (fr)
CN (1) CN108135886A (fr)
BR (1) BR112018001116A2 (fr)
CA (1) CA2992796A1 (fr)
EA (1) EA201890346A1 (fr)
MA (1) MA42519A (fr)
WO (1) WO2017017165A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7048863B2 (ja) * 2016-08-26 2022-04-06 武田薬品工業株式会社 非アルコール性脂肪肝疾患の治療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035039A1 (fr) * 2001-10-25 2003-05-01 Depomed, Inc. Traitement utilisant une dose posologique de losartan a retention gastrique
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
CN104817534A (zh) * 2004-03-03 2015-08-05 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途

Also Published As

Publication number Publication date
CN108135886A (zh) 2018-06-08
JP2018521077A (ja) 2018-08-02
EP3328381A1 (fr) 2018-06-06
CA2992796A1 (fr) 2017-02-02
EA201890346A1 (ru) 2018-08-31
US20200179369A1 (en) 2020-06-11
BR112018001116A2 (pt) 2018-09-11
WO2017017165A1 (fr) 2017-02-02

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
IL253945A0 (en) kdm1a inhibitors to treat the disease
EP3359171C0 (fr) Utilisation d'akkermansia muciniphila pour traiter des états inflammatoires
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
MA43190A (fr) Traitement de la dyslipidémie mixte
MA47719A (fr) Esketamine pour le traitement de la dépression
DK3197838T3 (da) Anammoxproces ved spildevandsanlæg
MA45429A (fr) Polythérapie pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
MA50409A (fr) Polythérapies pour le traitement du cancer
MA41555A (fr) Polythérapie pour le traitement du cancer
MA41123A (fr) Polythérapie pour le traitement du cancer
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA46999A (fr) Oligonucléotides modifiés pour traiter la polykystose rénale
DK3326635T3 (da) Behandling og forebyggelse af forkølelse ved hjælp af povidon-iod
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
HUE060167T2 (hu) Diabéteszes nefropátia vagy diabéteszes vesebetegségek megelõzésére vagy kezelésére szolgáló vegyület
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
MA41202A (fr) Copolymères polydiallymine réticulé pour le traitement du diabète de type 2